文献速递毛发、甲与色素性疾病

口服JAK抑制剂联合308nm准分子激光治疗儿童进展期白癜风的多中心研究

Efficacy of oral JAK inhibitors combined with 308-nm excimer laser in pediatric progressive vitiligo: A multicenter study.
PubMed 文献 · J Am Acad Dermatol · 2026-03-02

这项多中心、前瞻性、单盲随机对照试验纳入188例2至18岁进展期白癜风患儿,治疗48周。A组口服JAK抑制剂联合308nm准分子激光,B组外用他克莫司联合308nm准分子激光。A组复色率显著高于B组(P < .001),不良事件轻至中度且耐受良好。

要点

  • 口服JAK抑制剂联合308nm准分子激光可显著提高患儿复色率。
  • 不良事件以轻至中度为主,总体耐受性良好。
  • 疗效与年龄、病程、皮损部位及毛囊脱色素相关。

核心结论

  • 口服JAK抑制剂联合308nm准分子激光治疗儿童进展期白癜风显示出有前景的疗效与安全性,支持其作为潜在治疗选择。

研究设计与样本

  • 多中心、前瞻性、单盲随机对照试验,纳入188例2至18岁进展期白癜风患儿,治疗48周。
  • A组接受口服JAK抑制剂联合308nm准分子激光治疗,B组接受外用他克莫司联合308nm准分子激光治疗。
  • 主要结局为采用白癜风面积评分指数评估的复色率。

主要发现

  • A组复色率显著高于B组(P < .001)。
  • 不良事件为轻至中度,耐受性良好。
  • 治疗反应与年龄、病程、皮损部位及毛囊脱色素相关。

关键数值与推荐

  • 主要结局为白癜风面积评分指数评估的复色率,A组显著高于B组(P < .001)。

临床怎么用

  • 对于儿童进展期白癜风,可考虑口服JAK抑制剂联合308nm准分子激光作为治疗选项,但需结合年龄、病程、皮损部位及毛囊脱色素情况评估治疗反应。

局限性

  • 单盲设计、样本量及随访时间有限、单一对照限制了关于长期疗效与安全性的外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment options for progressive vitiligo in children are limited, with current therapies often lacking sustained efficacy and safety. OBJECTIVE: To evaluate the efficacy and safety of Janus kinase inhibitor combined with 308-nm excimer laser therapy in children with progressive vitiligo. METHODS: This multicenter, prospective, single-blind randomized controlled trial enrolled 188 children aged 2∼18 years with progressive vitiligo who received treatment for 48 weeks. Group A received an oral Janus kinase inhibitor combined with 308-nm excimer laser therapy, while Group B received topical tacrolimus combined with 308-nm excimer laser therapy. The primary outcome was the rate of repigmentation assessed by the Vitiligo Area Scoring Index. RESULTS: Group A exhibited significantly higher repigmentation rates than Group B (P < .001), with mild to moderate adverse events and good tolerability. Treatment response was correlated with age, disease duration, lesion location, and follicular depigmentation. LIMITATIONS: The single-blind design, limited sample size and follow-up, and single comparator restrict generalizability regarding long-term efficacy and safety. CONCLUSION: Janus kinase inhibitor combined with 308-nm excimer laser therapy demonstrates promising efficacy and safety in pediatric progressive vitiligo, supporting its potential as a therapeutic option.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Chang S, Zhang L, Liu B, et al. Efficacy of oral JAK inhibitors combined with 308-nm excimer laser in pediatric progressive vitiligo: A multicenter study. J Am Acad Dermatol. 2026. PMID: 41780599. doi:10.1016/j.jaad.2026.02.096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。